Alnylam Pharmaceuticals heads into its Q1 2026 earnings today with options traders sending a strikingly bullish signal — the most bullish in at least a year.
The put/call ratio dropped to 0.39 on May 19, three standard deviations below its 20-day mean of 0.47. That is the lowest reading in the past 52 weeks, against a full-year low of 0.36. The data points to an unusually sharp tilt toward calls ahead of the release — not routine optimism, but something much more directional than the stock's recent average. That positioning is notable given the price backdrop: ALNY is down 5% over the past month at $294.30, even as it bounced 2.8% on Tuesday alone. The stock has spent much of 2026 well below its January levels, making the call-side conviction in options markets a genuine contrast.
Short interest does not tell the same bullish story — but it is not threatening either. Bears hold roughly 3.7% of the free float, down 3.5% over the past week. Borrow is cheap at under 0.40% APR, and availability is extremely loose at over 6,500% of short interest. There are no signs of a squeeze setup or mounting short-side aggression. The lending market is effectively wide open.
Analyst opinion is broadly constructive but dispersed on valuation. Citigroup initiated coverage with a Buy and a $380 target yesterday — notable timing, ahead of today's print. Most bulls are clustered well above the current price: HC Wainwright holds a $510 target, Truist a $505, and RBC Capital an Outperform at $445. Wells Fargo sits at the cautious end with Equal-Weight at $377. The mean target of $447 implies roughly 52% upside from current levels. The one meaningful dissent in recent months came from Jefferies, which downgraded to Hold in March with a $330 target — a move that flagged valuation risk when the stock was higher. Bulls point to Alnylam's RNAi pipeline leadership and strong earnings momentum (EPS momentum scores in the 74th–76th percentile). Bears flag the need for ongoing capital deployment, commercialisation risk, and a demanding valuation: the P/E runs at 25x and EV/EBITDA at 25.7x, both compressing over the past 30 days.
Institutional ownership adds an interesting layer. Capital Research holds 15.3% of shares and added over 1.5 million shares in the most recent reporting period. T. Rowe Price sits at just under 5%, having built a position of over 3 million shares in the last quarter. Two Sigma added 1.4 million shares. That institutional accumulation stands in contrast to the stock's weak year-to-date performance — large active managers have been adding while the price lagged. Past earnings prints have offered little encouragement for bulls on reaction day: the last two quarterly results each produced declines of roughly 1.7–2.6% on the day and 1.8–3.2% over the following five sessions.
The Q1 print is therefore less a test of whether the RNAi franchise is intact and more a question of whether commercial execution and forward guidance can justify the call-heavy positioning that options traders have built — and the conviction that a core of large institutional buyers has demonstrated with their wallets.
See the live data behind this article on ORTEX.
Open ALNY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
